Key Specifications Table
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|5.00502.0001||Glass bottle||5 mg||
|Overview||A cell-permeable tetrapeptidylsulfonylfluoride-based irreversible proteasome inhibitor that selectively inhibits the hydrolysis of Suc-LLVY-AMC (Cat. No. 539142) by the β5 chymotrypsin-like activity (IC50 = 7 nM using yeast 20S proteasome), while exhibiting much reduced potency against Z-LLE-AMC (Cat. No. 539141) hydrolysis by the β1 caspase-like activity or Z-LLR-AMC hydrolysis by the β2 trypsin-like activity (29% and 75% inhibition, respectively, with 200 µM inhibitor). One hour inhibitor treatment at 5 µM in HEK cultures is shown to completely abolish β5 labeling by the proteasome probe MV151, while only partial MV151 blockage is seen with β1 and β2 at an inhibitor concentration of 50 µM.
Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
|Synonyms||Cbz-Leu₄-SF, Cbz-LLLL-SF, Z-Leu₄-SF, Z-L₄-SF, Cbz-Leu-Leu-Leu-Leu-ψ-[CH2SO2]-F|
|References||Brouwer. A.J., et al. 2013. J. Med. Chem. 55, 10995.|
|Structure formula Image|
|Primary Target||β5 chymotrypsin-like activity of 20S proteasome|
|Purity||≥98% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Brouwer. A.J., et al. 2013. J. Med. Chem. 55, 10995.|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.